2014—2019年我国六城市骨质疏松症患者药物治疗现状调查分析

Investigation and analysis of the current situation of anti-osteoporosis drugs in six cities in China during 2014—2019

目的分析2014―2019年我国部分医院抗骨质疏松症药物应用情况,并给出合理化建议,以期为临床合理用药提供参考。方法随机抽取参与“医院处方分析”课题组研究的我国6个城市(北京、成都、广州、杭州、上海及天津)84家医院骨质疏松症患者的处方信息,计算抗骨质疏松症药物的用药频度(DDDs)、限定日费用(DDC)值、销售金额增长率等,以分析临床应用情况。结果本研究共纳入6328029张处方,统计结果显示,骨质疏松症女性患者明显多于男性,且女性患者比例呈逐年上升趋势。6个城市抗骨质疏松症药物销售总金额除了2017年有所下降外,其余年份均稳步增长,销售总金额最高的药物是唑来膦酸。6个城市使用频率最高的药物是碳酸钙D3(600 mg)和骨化三醇(口服),且两者DDDs值逐年增长。结论6个城市骨质疏松症用药总金额呈上升趋势,各城市骨质疏松症患者药物使用情况虽有所差异,但总体上符合指南推荐用药,应对个别药物的安全性有所警惕。

Objective The application of anti-osteoporosis drugs in some hospitals from 2014 to 2019,and give reason⁃able suggestions,in order to provide reference for clinical rational drug use.Methods Prescriptions of osteoporosis patients in 84 hospitals participating in the research of"Hospital Prescription Analysis"were randomly selected.Defined daily dose system(DDDs),daily drug cost(DDC)values,sales growth rate,etc.of anti-osteoporosis drugs were calculated to analyze clinical applications.Results A total of 6328029 prescriptions were included in this study.The statistical results showed that there were significantly more female patients with osteoporosis than male patients,and the proportion of female patients had been in⁃creasing year by year.The total consumption sum of the six cities increased steadily except for the decrease in 2017.The drug with the highest total consumption sum was zoledronic acid.The most frequently used drugs in each city were calcium carbon⁃ate D3(600 mg)and calcitriol(oral),and the value of DDDs was increasing year by year.Conclusion The total amount of os⁃teoporosis in 6 cities is on the rise.There are differences in the use of drugs in patients with osteoporosis in different regions.Generally,the drugs used in the practices are in line with the guidelines.The safety of individual drugs should be vigilant.